<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04226742</url>
  </required_header>
  <id_info>
    <org_study_id>HS#2019-4901</org_study_id>
    <secondary_id>1R34MH113616-01A1</secondary_id>
    <nct_id>NCT04226742</nct_id>
  </id_info>
  <brief_title>Evaluation of a Crowd-Powered Web Platform for Depression and Anxiety</brief_title>
  <official_title>Evaluation of the Crowd-Powered Web Platform for Accumulative Depression and Anxiety Plans and Treatment (ADAPT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mental Health America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      100 participants will be enrolled in a two-armed randomized controlled trial of the
      Accumulated Depression and Anxiety Plans and Treatments (ADAPT) platform which integrates
      internet Cognitive Behavioral Therapy (iCBT) to determine impact on symptoms of depression
      and anxiety. This trial will pilot the effectiveness of the ADAPT platform, and evaluate the
      extent to which the ADAPT platform engages putative targets of personal relevance, skills
      use, and skills mastery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will enroll 100 participants in a two-armed randomized controlled trial of
      the ADAPT platform (iCBT). Participants will be randomly assigned to receive either the ADAPT
      platform (treatment) or a similar self-guided platform (control) that contains the didactic
      material (learning) but lacks the ADAPT platforms &quot;crowd&quot; features. Participants will use
      their assigned platform for a treatment period of 8 weeks. Participants will receive trial
      assessments at baseline, week 4, and week 8 (post-treatment). Follow-up evaluations will
      occur at 16 weeks to evaluate maintenance of gains. This pilot effectiveness trial aims to
      determine the impact on symptoms of depression and anxiety and whether the platform engages
      the putative targets of personal relevance, relationship, resulting in increased skills
      mastery and skills use.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to receive either the treatment condition (ADAPT platform, iCBT platform comprised of didactic and interactive content), or a control condition (iCBT comparison platform comprised only of didactic content).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants will be unaware of which condition they have been assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Depression at 16 weeks</measure>
    <time_frame>Change from Baseline to Week 4, Week 8, and Week 16</time_frame>
    <description>The primary outcome of symptoms of depression will be measured with the self-report Depression Anxiety Stress Scale (DASS) which produces a single score from 0-56 as well as subscores for depression that ranges from 0-56.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Anxiety at 16 weeks</measure>
    <time_frame>Change from Baseline to Week 4, Week 8, and Week 16</time_frame>
    <description>The primary outcome of symptoms of anxiety will be measured with the self-report DASS, which produces a single score from 0-56.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Diagnostic Status at 16 weeks</measure>
    <time_frame>Change from Baseline to Week 4, Week 8, and Week 16</time_frame>
    <description>A secondary outcome is diagnostic status as assessed using the Structured Clinical Interview for DSM-5 (SCID-5). Diagnostic status will also be used as a moderator of change in depressive and anxiety symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in use of cognitive and behavioral skills at 16 weeks</measure>
    <time_frame>Change from Baseline to Week 4, Week 8, and Week 16</time_frame>
    <description>A secondary outcome is the Cognitive and Behavioral Response to Stress Scale (CB-RSS), which produces separate scores for frequency and usefulness of cognitive and behavioral skills. Scores for frequency and usefulness each range from 0-54.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Self-efficacy at 16 weeks</measure>
    <time_frame>Change from Baseline to Week 4, Week 8, and Week 16</time_frame>
    <description>A secondary outcome is the Coping Self-Efficacy (CSE), which produces a single score that ranges from 0-260.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Accountability at 16 weeks</measure>
    <time_frame>Change from Baseline to Week 4, Week 8, and Week 16</time_frame>
    <description>A secondary outcome is the Supportive Accountability Questionnaire (SAQ), which produces a single score than ranges from 7-91. The SAQ also produces scores of subscales including bond, accountability, and legitimacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Social Functioning at 16 weeks</measure>
    <time_frame>Change from Baseline to Week 4, Week 8 and Week 16</time_frame>
    <description>Functioning will be assessed with the Patient-Reported Outcomes Measurement Information System (PROMIS) Ability to Participate in Social Roles and Activities Scale which produces raw scores from 8 to 40. These scores can be standardized to be reported as T-scores that have a mean of 50 and a standard deviation of 10.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Depression, Anxiety</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomly assigned to this condition will receive the ADAPT platform (treatment) for a treatment period of 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomly assigned to this condition will receive a similar self-guided platform (control) for a treatment period of 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ADAPT Platform (Treatment)</intervention_name>
    <description>The ADAPT platform consists of 2 modules based on evidence-based strategies from cognitive-behavioral therapy including cognitive restructuring and behavioral experiments. The platform includes didactic material, interactive tools, and crowd-features. Crowd-features are present to increase personal relevance of content and to promote engagement with the ADAPT platform through accountability. Crowd-features include requesting, responding, and exemplars.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ADAPT Comparison (Control)</intervention_name>
    <description>The control platform is a self-guided version of the ADAPT platform that includes no crowd-features. As such it will include only didactic material on cognitive restructuring and behavioral experiments and interactive tools.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Completion of the Mental Health America Screening to Supports (MHA S2S) or
             significant mood and anxiety symptoms as defined by an accepted cut-off on a validated
             measure the Depression Anxiety and Stress Scale (DASS). The accepted cut-off is scores
             greater than 22;

          -  2) able to speak and read English;

          -  3) at least 18 years of age.

        Exclusion Criteria:

          -  1) severe suicidality (has ideation, plan, and intent)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen M Schueller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen M Schueller, PhD</last_name>
    <phone>949-824-3850</phone>
    <email>s.schueller@uci.edu</email>
  </overall_contact>
  <reference>
    <citation>Dear BF, Titov N, Schwencke G, Andrews G, Johnston L, Craske MG, McEvoy P. An open trial of a brief transdiagnostic internet treatment for anxiety and depression. Behav Res Ther. 2011 Dec;49(12):830-7. doi: 10.1016/j.brat.2011.09.007. Epub 2011 Sep 28.</citation>
    <PMID>21993153</PMID>
  </reference>
  <reference>
    <citation>Titov N, Dear BF, Schwencke G, Andrews G, Johnston L, Craske MG, McEvoy P. Transdiagnostic internet treatment for anxiety and depression: a randomised controlled trial. Behav Res Ther. 2011 Aug;49(8):441-52. doi: 10.1016/j.brat.2011.03.007. Epub 2011 Apr 3.</citation>
    <PMID>21679925</PMID>
  </reference>
  <reference>
    <citation>van Ballegooijen W, Cuijpers P, van Straten A, Karyotaki E, Andersson G, Smit JH, Riper H. Adherence to Internet-based and face-to-face cognitive behavioural therapy for depression: a meta-analysis. PLoS One. 2014 Jul 16;9(7):e100674. doi: 10.1371/journal.pone.0100674. eCollection 2014.</citation>
    <PMID>25029507</PMID>
  </reference>
  <reference>
    <citation>Schueller SM, Mohr DC. Initial Field Trial of a Coach-Supported Web-Based Depression Treatment. Int Conf Pervasive Comput Technol Healthc. 2015 Aug;2015. doi: 10.4108/icst.pervasivehealth.2015.260115. Epub 2015 Aug 3.</citation>
    <PMID>26640741</PMID>
  </reference>
  <reference>
    <citation>Muñoz RF. Using evidence-based internet interventions to reduce health disparities worldwide. J Med Internet Res. 2010 Dec 17;12(5):e60. doi: 10.2196/jmir.1463.</citation>
    <PMID>21169162</PMID>
  </reference>
  <reference>
    <citation>Muñoz RF, Aguilera A, Schueller SM, Leykin Y, Pérez-Stable EJ. From online randomized controlled trials to participant preference studies: morphing the San Francisco Stop Smoking site into a worldwide smoking cessation resource. J Med Internet Res. 2012 Jun 27;14(3):e64. doi: 10.2196/jmir.1852.</citation>
    <PMID>22739225</PMID>
  </reference>
  <reference>
    <citation>Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007 Mar 6;146(5):317-25.</citation>
    <PMID>17339617</PMID>
  </reference>
  <reference>
    <citation>Lovibond, S. H., &amp; Lovibond, P. F. (1993). Manual for the Depression Anxiety Stress Scales (DASS). Psychology Foundation Monograph, University of New South Wales.</citation>
  </reference>
  <reference>
    <citation>Muñoz, R. F., Bunge, E. L., Chen, K., Schueller, S. M., Bravin, J. I., Shaughnessy, E. A., &amp; Pérez- Stable, E. J. (2015). Massive open online interventions: A novel model for delivering behavioral-health services worldwide. Clinical Psychological Science. Advanced Online Publication. http://doi.org/10.1177/2167702615583840</citation>
  </reference>
  <reference>
    <citation>MacArthur Foundation's Initiative (2004). The Macarthur initiative on depression and primary care at Dartmouth and Duke: Depression management toolkit. Hanover, NH: Dartmouth.</citation>
  </reference>
  <reference>
    <citation>First, M. B., Williams, J. B. W., Karg, R. S., &amp; Spitzer, R. L. (2015). Structured clinical interview for DSM-5 disorders, clinician version (SCID-5-CV). Arlington, VA: American Psychiatric Association.</citation>
  </reference>
  <reference>
    <citation>Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995 Mar;33(3):335-43.</citation>
    <PMID>7726811</PMID>
  </reference>
  <reference>
    <citation>Gorka SM, Lieberman L, Klumpp H, Kinney KL, Kennedy AE, Ajilore O, Francis J, Duffecy J, Craske MG, Nathan J, Langenecker S, Shankman SA, Phan KL. Reactivity to unpredictable threat as a treatment target for fear-based anxiety disorders. Psychol Med. 2017 Oct;47(14):2450-2460. doi: 10.1017/S0033291717000964. Epub 2017 Apr 24.</citation>
    <PMID>28436351</PMID>
  </reference>
  <reference>
    <citation>Gorka SM, Burkhouse KL, Afshar K, Phan KL. Error-related brain activity and internalizing disorder symptom dimensions in depression and anxiety. Depress Anxiety. 2017 Nov;34(11):985-995. doi: 10.1002/da.22648. Epub 2017 Sep 20.</citation>
    <PMID>28940987</PMID>
  </reference>
  <reference>
    <citation>Burkhouse KL, Gorka SM, Afshar K, Phan KL. Neural reactivity to reward and internalizing symptom dimensions. J Affect Disord. 2017 Aug 1;217:73-79. doi: 10.1016/j.jad.2017.03.061. Epub 2017 Mar 29.</citation>
    <PMID>28391111</PMID>
  </reference>
  <reference>
    <citation>Duffecy, J., Cai, X., &amp; Mohr, D. C. (2013). Supportive accountability: Measurement of a framework for adherence to behavioral intervention technologies. International Society for Research on Internet Interventions, Chicago, IL.</citation>
  </reference>
  <reference>
    <citation>Miner AS, Schueller SM, Lattie EG, Mohr DC. Creation and validation of the Cognitive and Behavioral Response to Stress Scale in a depression trial. Psychiatry Res. 2015 Dec 30;230(3):819-25. doi: 10.1016/j.psychres.2015.10.033. Epub 2015 Oct 30.</citation>
    <PMID>26553147</PMID>
  </reference>
  <reference>
    <citation>Chesney MA, Neilands TB, Chambers DB, Taylor JM, Folkman S. A validity and reliability study of the coping self-efficacy scale. Br J Health Psychol. 2006 Sep;11(Pt 3):421-37.</citation>
    <PMID>16870053</PMID>
  </reference>
  <reference>
    <citation>Hahn EA, Devellis RF, Bode RK, Garcia SF, Castel LD, Eisen SV, Bosworth HB, Heinemann AW, Rothrock N, Cella D; PROMIS Cooperative Group. Measuring social health in the patient-reported outcomes measurement information system (PROMIS): item bank development and testing. Qual Life Res. 2010 Sep;19(7):1035-44. doi: 10.1007/s11136-010-9654-0. Epub 2010 Apr 25.</citation>
    <PMID>20419503</PMID>
  </reference>
  <reference>
    <citation>Holländare F, Johnsson S, Randestad M, Tillfors M, Carlbring P, Andersson G, Engström I. Randomized trial of Internet-based relapse prevention for partially remitted depression. Acta Psychiatr Scand. 2011 Oct;124(4):285-94. doi: 10.1111/j.1600-0447.2011.01698.x. Epub 2011 Mar 14.</citation>
    <PMID>21401534</PMID>
  </reference>
  <reference>
    <citation>Titov N, Dear BF, Johnston L, Lorian C, Zou J, Wootton B, Spence J, McEvoy PM, Rapee RM. Improving adherence and clinical outcomes in self-guided internet treatment for anxiety and depression: randomised controlled trial. PLoS One. 2013 Jul 3;8(7):e62873. doi: 10.1371/journal.pone.0062873. Print 2013.</citation>
    <PMID>23843932</PMID>
  </reference>
  <reference>
    <citation>Kelders SM, Bohlmeijer ET, Pots WT, van Gemert-Pijnen JE. Comparing human and automated support for depression: Fractional factorial randomized controlled trial. Behav Res Ther. 2015 Sep;72:72-80. doi: 10.1016/j.brat.2015.06.014. Epub 2015 Jul 6.</citation>
    <PMID>26196078</PMID>
  </reference>
  <reference>
    <citation>Smith P, Scott R, Eshkevari E, Jatta F, Leigh E, Harris V, Robinson A, Abeles P, Proudfoot J, Verduyn C, Yule W. Computerised CBT for depressed adolescents: Randomised controlled trial. Behav Res Ther. 2015 Oct;73:104-10. doi: 10.1016/j.brat.2015.07.009. Epub 2015 Jul 21.</citation>
    <PMID>26301756</PMID>
  </reference>
  <reference>
    <citation>Johnston L, Titov N, Andrews G, Dear BF, Spence J. Comorbidity and internet-delivered transdiagnostic cognitive behavioural therapy for anxiety disorders. Cogn Behav Ther. 2013;42(3):180-92. doi: 10.1080/16506073.2012.753108. Epub 2013 Mar 4.</citation>
    <PMID>23458319</PMID>
  </reference>
  <reference>
    <citation>Titov N, Dear BF, Staples LG, Bennett-Levy J, Klein B, Rapee RM, Shann C, Richards D, Andersson G, Ritterband L, Purtell C, Bezuidenhout G, Johnston L, Nielssen OB. MindSpot Clinic: An Accessible, Efficient, and Effective Online Treatment Service for Anxiety and Depression. Psychiatr Serv. 2015 Oct;66(10):1043-50. doi: 10.1176/appi.ps.201400477. Epub 2015 Jul 1.</citation>
    <PMID>26130001</PMID>
  </reference>
  <reference>
    <citation>Kirkpatrick T, Manoukian L, Dear BF, Johnston L, Titov N. A feasibility open trial of internet-delivered cognitive-behavioural therapy (iCBT) among consumers of a non-governmental mental health organisation with anxiety. PeerJ. 2013 Nov 28;1:e210. doi: 10.7717/peerj.210. eCollection 2013.</citation>
    <PMID>24349897</PMID>
  </reference>
  <reference>
    <citation>van Mierlo T. The 1% rule in four digital health social networks: an observational study. J Med Internet Res. 2014 Feb 4;16(2):e33. doi: 10.2196/jmir.2966.</citation>
    <PMID>24496109</PMID>
  </reference>
  <reference>
    <citation>Christensen H, Griffiths K, Groves C, Korten A. Free range users and one hit wonders: community users of an Internet-based cognitive behaviour therapy program. Aust N Z J Psychiatry. 2006 Jan;40(1):59-62.</citation>
    <PMID>16403040</PMID>
  </reference>
  <reference>
    <citation>Eysenbach G. The law of attrition. J Med Internet Res. 2005 Mar 31;7(1):e11.</citation>
    <PMID>15829473</PMID>
  </reference>
  <reference>
    <citation>Mohr DC, Tomasino KN, Lattie EG, Palac HL, Kwasny MJ, Weingardt K, Karr CJ, Kaiser SM, Rossom RC, Bardsley LR, Caccamo L, Stiles-Shields C, Schueller SM. IntelliCare: An Eclectic, Skills-Based App Suite for the Treatment of Depression and Anxiety. J Med Internet Res. 2017 Jan 5;19(1):e10. doi: 10.2196/jmir.6645.</citation>
    <PMID>28057609</PMID>
  </reference>
  <reference>
    <citation>Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008 Aug;40(3):879-91.</citation>
    <PMID>18697684</PMID>
  </reference>
  <reference>
    <citation>Braithwaite SR, Giraud-Carrier C, West J, Barnes MD, Hanson CL. Validating Machine Learning Algorithms for Twitter Data Against Established Measures of Suicidality. JMIR Ment Health. 2016 May 16;3(2):e21. doi: 10.2196/mental.4822.</citation>
    <PMID>27185366</PMID>
  </reference>
  <reference>
    <citation>O'Dea, B., Wan, S., Batterham, P. J., Calear, A. L., Paris, C., &amp; Christensen, H. (2015). Detecting suicidality on Twitter. Internet Interventions, 2(2), 183-188. http://dx.doi.org/10.1016/j.invent.2015.03.005</citation>
  </reference>
  <reference>
    <citation>Nguyen, T., O'Dea, B., Larsen, M., Phung, D., Venkatesh, S., &amp; Christensen, H. (2015, November). Differentiating sub-groups of online depression-related communities using textual cues. In International Conference on Web Information Systems Engineering (pp. 216-224). Springer International Publishing.</citation>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual Participant Data will be deposited into the NIH data repository.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will become available immediately following publication, no end date.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

